Literature DB >> 17888540

The utility of cyclodextrins for enhancing oral bioavailability.

Rebecca L Carrier1, Lee A Miller, Imran Ahmed.   

Abstract

Cyclodextrins (CD) have been utilized extensively in pharmaceutical formulations to enhance oral bioavailability. A critical review of the literature in which cyclodextrins were utilized for this purpose was conducted. The goal of this review was to determine if quantitative guidelines for drug and cyclodextrin properties necessary for bioavailability enhancement using cyclodextrins could be extracted. Twenty-eight studies were examined in which the focus was on the use of cyclodextrins as solubilizers to enhance bioavailability. Commonly observed factors included: utilization of pre-formed complex rather than physical mixtures, drug hydrophobicity (logP > 2.5), low drug solubility (typically< 1 mg/ml), moderate binding constant (< 5000 M(-1)), low dose (< 100 mg), and low CD:drug ratio (< 2:1). These general guidelines, however, did not apply to all studies. Quantitative guidelines useful to a formulation scientist considering the use of cyclodextrins were difficult to develop due to missing information and the complicated manner in which drug and cyclodextrin properties interact to influence key drug delivery processes (e.g., dissolution, absorption). The mechanisms by which cyclodextrins influence these processes, again emphasizing solubilization capabilities, are discussed to provide further insight into why cyclodextrins will increase bioavailability in certain cases but not influence or possibly decrease bioavailability in others.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17888540     DOI: 10.1016/j.jconrel.2007.07.018

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  68 in total

1.  Enhanced solubility, stability, and transcorneal permeability of δ-8-tetrahydrocannabinol in the presence of cyclodextrins.

Authors:  Ketan Hippalgaonkar; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

Review 2.  The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs.

Authors:  Arik Dahan; Jonathan M Miller
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

3.  Pharmacokinetics and pharmacodynamics of nasally delivered midazolam.

Authors:  Manuel Haschke; Katja Suter; Sarah Hofmann; Robert Witschi; Johannes Fröhlich; Georgios Imanidis; Jürgen Drewe; Thomas A Briellmann; Franz E Dussy; Stephan Krähenbühl; Christian Surber
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

4.  Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Nano Today       Date:  2010-08-01       Impact factor: 20.722

5.  Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

6.  Preparation and characterization of inclusion complexes of a hemisuccinate ester prodrug of delta9-tetrahydrocannabinol with modified beta-cyclodextrins.

Authors:  Sampada B Upadhye; Swapnil J Kulkarni; Soumyajit Majumdar; Mitchell A Avery; Waseem Gul; Mahmoud A ElSohly; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2010-03-24       Impact factor: 3.246

7.  Studies on the effect of water-soluble polymers on drug-cyclodextrin complex solubility.

Authors:  Rajashree S Hirlekar; Suneeta N Sonawane; Vilasrao J Kadam
Journal:  AAPS PharmSciTech       Date:  2009-06-27       Impact factor: 3.246

8.  Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs.

Authors:  Toshiyuki Niwa; Satoru Miura; Kazumi Danjo
Journal:  Pharm Res       Date:  2011-05-28       Impact factor: 4.200

9.  Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes.

Authors:  Sateeshkumar Sathigari; Gurkishan Chadha; Y-H Phillip Lee; Nydeia Wright; Daniel L Parsons; Vijay K Rangari; Oladiran Fasina; R Jayachandra Babu
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

10.  Preformulation study of the inclusion complex irbesartan-beta-cyclodextrin.

Authors:  Rajashree Hirlekar; Vilasrao Kadam
Journal:  AAPS PharmSciTech       Date:  2009-03-13       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.